Blue Sky Pediatric Speech Therapy, Inc. | |
14920 Westminster Way N Ste 1a, Shoreline, WA 98133-6445 | |
(206) 306-9999 | |
(206) 306-9997 |
Full Name | Blue Sky Pediatric Speech Therapy, Inc. |
---|---|
Type | Facility |
Speciality | Speech-language Pathologist |
Location | 14920 Westminster Way N Ste 1a, Shoreline, Washington |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1306112040 | NPI | - | NPPES |
1689735904 | Other | WA | NPI |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
235Z00000X | Speech-language Pathologist | LL00003279 (Washington) | Primary |
Mailing Address | Practice Location Address |
---|---|
Blue Sky Pediatric Speech Therapy, Inc. 14920 Westminster Way N Ste 1a, Shoreline, WA 98133-6445 Ph: (206) 306-9999 | Blue Sky Pediatric Speech Therapy, Inc. 14920 Westminster Way N Ste 1a, Shoreline, WA 98133-6445 Ph: (206) 306-9999 |
News Archive
Pfizer has announced that it has entered into an agreement to acquire Coley Pharmaceutical Group, a publicly-held biopharmaceutical company specializing in vaccine adjuvant technology and a new class of immunomodulatory drug candidates designed to fight cancers, allergy and asthma disorders, and autoimmune diseases.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it issued a letter to its shareholders advising that it had filed for patent protection worldwide and expects to enter Phase I clinical trials for its principal drug, Adva-27a, beginning with GMP manufacturing and animal tox studies.
One-quarter of women who should take hormone-blocking therapies as part of their breast cancer treatment either do not start or do not complete the five-year course, according to a new study led by University of Michigan Comprehensive Cancer Center researchers.
A new health economic analysis, published today online in Thrombosis and Haemostasis, suggested that Boehringer Ingelheim's novel oral direct thrombin inhibitor, dabigatran etexilate, is cost-effective compared to current treatment options, particularly in "real-world" clinical practice.
› Verified 9 days ago
Kristi Jill Marion, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2402 Nw 195th Pl, Shoreline, WA 98177 Phone: 206-364-3777 Fax: 206-364-3999 | |
Mrs. Jisun Park, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 816 Ne 190th St, Shoreline, WA 98155 Phone: 206-364-3777 | |
April Grace Lagutang Lloyd, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2818 Ne 145th St, Shoreline, WA 98155 Phone: 206-418-2900 | |
Lisa J Vanhorne, MSCCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 340 Nw 177th St, Shoreline, WA 98177 Phone: 206-546-5012 | |
Sarah Burt, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2402 Nw 195th Pl, Shoreline, WA 98177 Phone: 206-364-3777 Fax: 206-364-3999 | |
Francesca Blasen, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2402 Nw 195th Pl, Shoreline, WA 98177 Phone: 206-364-3777 Fax: 206-364-3999 | |
Andrea Ryan, MACCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 16357 Aurora Ave N, Shoreline, WA 98133 Phone: 206-542-3103 Fax: 206-542-4813 |